Cronos Group (TSE:CRON) Trading Up 14.2% – Still a Buy?

Cronos Group Inc. (TSE:CRONGet Free Report)’s stock price was up 14.2% on Thursday . The stock traded as high as C$4.34 and last traded at C$4.34. Approximately 494,519 shares traded hands during trading, an increase of 198% from the average session volume of 166,217 shares. The stock had previously closed at C$3.80.

Analyst Ratings Changes

Separately, TD boosted their target price on shares of Cronos Group from C$4.50 to C$5.50 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cronos Group presently has a consensus rating of “Buy” and an average price target of C$4.75.

Read Our Latest Analysis on CRON

Cronos Group Stock Up 12.6%

The stock has a market cap of C$1.60 billion, a PE ratio of -188.00, a price-to-earnings-growth ratio of 0.12 and a beta of 1.13. The business has a fifty day moving average of C$3.90 and a 200-day moving average of C$3.70. The company has a debt-to-equity ratio of 0.12, a current ratio of 21.87 and a quick ratio of 24.01.

Cronos Group (TSE:CRONGet Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported C$0.06 earnings per share for the quarter. The business had revenue of C$62.86 million for the quarter. Cronos Group had a negative return on equity of 0.19% and a negative net margin of 1.29%. Equities research analysts anticipate that Cronos Group Inc. will post -0.26 earnings per share for the current year.

About Cronos Group

(Get Free Report)

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.

See Also

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.